Recent Updates
Recently added Catalysts

certepetide

Phase 2

Cholangiocarcinoma | Peptides | Oncology |Lisata Therapeutics, Inc.|Trials Updated: Sep 28, 2026

certepetide development status

Highest phase Phase 2
Registered trials 5 across 3 sponsors since May 2018

certepetide target and mechanism

Target class-Tide (Peptide)
ModalityPeptides

Also known as CEND-1, LSTA1, iRGD

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials3
Total Enrollment146

FDA Designations

ORPHAN_DRUG

certepetide clinical trials

certepetide · 3 trials · 10 indications

Phase 2 1Phase 1/2 1Phase 1 1
NCT05712356A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid TumorsCholangiocarcinoma
COMPLETED66 Analytics
PHASE2COMPLETED
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
CholangiocarcinomaUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of Subjects Experiencing Any Adverse Event
From time of consent until 30 days after treatment discontinuation, up to 18 months

The National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE) will be used to grade the intensity of adverse events throughout the study

Safety of CEND-1 mesured by AEs, SAEs and treatment related adverse events.
12 month

Adverse events (AEs), serious adverse events (SAEs), treatment related adverse events are included. The investigator should carry out judgment for investigational drug correlation.

Preliminary efficacy of CEND-1 mesured by ORR, DOR, DCR, OS, PFS ect.
12 month

Objective response rate (ORR), duration of response (DOR), disease control rate (DCR), overall survival (OS), progress-free survival (PFS), PFS rate, OS rate etc. are included.

Safe doses of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabine
Escalation Phase: From Day 1 of the run-in until Day 28 of Cycle 1 (cycle length=28 days)

Safety and toxicity profile of treatment regimen as measured by grade and frequency of adverse events, graded and documented according to the NCI CTCAE, version 5.0 guidelines

Optimal Biological Dose (OBD) of CEND-1 when given in combination
Expansion Phase: from baseline until treatment discontinuation and approximately 30 days after last dose (cycle length=28 days)

OBD will be determined by evaluating biomarkers (such as the tumor marker CA19-9 Response Rate), the ECOG Performance Status and the Disease Control Rate

Secondary Endpoints

Pharmacokinetics of CEND-1 when given alone or in combination with nabpaclitaxel and gemcitabine
Escalation phase: Predose, 3 minutes, 15 min, 30 min, 1 h, 4 h, 8 h postdose on Day 1 of the run-in and Day 1 of Cycle 1
Disease Control Rate (Complete Remission (CR) + Partial Remission (PR) + Stable Disease (SD)) associated with the administration of CEND-1 in combination with nabpaclitaxel and gemcitabine
Expansion Phase: from baseline until treatment discontinuation and approximately 30 days after last dose (cycle length=28 days)
Preliminary evidence of anti-tumor activity of CEND-1 when given in combination with nabpaclitaxel bound and gemcitabine by objective radiographic assessment according to RECIST 1.1
Expansion Phase: from baseline until treatment discontinuation and approximately 30 days after last dose (cycle length=28 days)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
LSTA1 arm for Untreated CholangiocarcinomaEXPERIMENTAL -
LSTA1 arm for Second-Line CholangiocarcinomaEXPERIMENTAL -
Placebo arm for Untreated CholangiocarcinomaPLACEBO_COMPARATOR -
Placebo arm for Second-Line CholangiocarcinomaPLACEBO_COMPARATOR -
CEND-1EXPERIMENTALCEND-1+paclitaxel (albumin-bound type)+gemcitabine
Part A (Dose Escalation)EXPERIMENTALSafety of ascending dose levels of CEND-1 in combination with gemcitabine and nab-paclitaxel will be evaluated. Patients will receive an IV bolus of CEND-1 on Day 1 of the 1-week run-in period. This is followed by one treatment cycle (28 days) with the CEND-1 / nab-paclitaxel (125mg/m\^2) / gemcitabine (1000mg/m\^2) combination given on Days 1, 8, 15.
Part B (Expansion)EXPERIMENTALSafety and early efficacy of CEND-1 in combination with nab-paclitaxel (125mg/m\^2) and gemcitabine (1000mg/m\^2) will be evaluated (dosing on Days 1, 8, 15 of the 28-day treatment cycle). Treatment cycles will be repeated every 4 weeks based on toxicity and response. Treatment may continue as long as there is perceived benefit or until disease progression.

Interventions

NameTypeDescription
certepetideDRUGLSTA1 3.2 mg/kg given as a slow IV push over 1 minute when standard treatment(s) are given
DurvalumabDRUG1500 mg of durvalumab IV administered over 1 hour every 21 days for 8 cycles then every 28 days for additional cycles
CisplatinDRUGcisplatin 25 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
GemcitabineDRUGgemcitabine 1000 mg/m² IV administered over 30 minutes on day 1 and day 8 every 21 days for up to 8 cycles
FOLFOX regimenDRUGThe following will be given every 14 days: * oxaliplatin 85 mg/m² and l-folinic acid 200 mg/m² or d,l-folinic acid 400 mg/m² concurrently, as a 2-hour IV infusion * fluorouracil (5-FU) 400 mg/m² will be given as an IV bolus over 5 minutes * fluorouracil (5-FU) 2400 mg/m² will be administered over 46 hours (via home-infusion pump)
PlaceboDRUGPlacebo given as a slow IV push over 1 minute when standard treatment(s) are given
CEND-1DRUGThe dose is specified according to the protocol. CEND-1+paclitaxel (albumin-bound type)+gemcitabine
Nab-paclitaxelDRUGNab-paclitaxel will be provided as solution to be administered via IV infusion.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites19

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy ≥ 3 months * At least one measurable lesion as assessed by RECIST 1.1 * Adequate organ and marrow function * Adequate contraception * Patients with either of the following: * Pathologic...

Countries:United StatesChinaAustralia
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

MEDIUMOct 29, 2026NCT05712356TRIAL_REMOVED: changed
MEDIUMOct 29, 2026NCT05712356TRIAL_REMOVED: changed
MEDIUMOct 29, 2026NCT05712356TRIAL_REMOVED: changed
MEDIUMOct 29, 2026NCT05712356TRIAL_REMOVED: changed

Frequently asked questions about certepetide

What is certepetide used for?

Certepetide is being studied in cholangiocarcinoma, including intrahepatic and extrahepatic bile duct cancer and gallbladder cancer. It is an investigational small molecule developed by Lisata Therapeutics and is not yet approved for commercial use. The Phase 2 study evaluated it in patients with advanced solid tumors when added to standard of care.

Who makes certepetide?

Certepetide is developed by Lisata Therapeutics, Inc., which trades on the Nasdaq under the ticker LSTA. The company is the sponsor of the clinical program evaluating the drug in cholangiocarcinoma and related biliary tract cancers.

What phase is certepetide in?

Certepetide is in Phase 2 development. The completed Phase 2 trial, NCT05712356, enrolled 66 patients with advanced solid tumors including cholangiocarcinoma and gallbladder cancer. The study was randomized, double-blind, and placebo-controlled, comparing the addition of LSTA1 to standard of care versus standard of care alone.

What clinical trials is certepetide in?

Certepetide has been evaluated in the Phase 2 trial NCT05712356, titled A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors. The trial enrolled 66 patients across sites in the United States and has been completed.

Is certepetide FDA approved?

Certepetide is not approved; it remains an investigational drug in clinical development. The FDA has granted it Orphan Drug designation for its cholangiocarcinoma program. Lisata Therapeutics continues to develop the asset, with the Phase 2 trial NCT05712356 completed.

Is certepetide the same as LSTA1?

Yes, LSTA1 is an alternative name for certepetide. The Phase 2 trial NCT05712356 refers to the drug as LSTA1 in its title, evaluating its addition to standard of care versus standard of care alone in patients with advanced solid tumors, including cholangiocarcinoma and gallbladder cancer.